Contact: NCI Press Office
NIH/National Cancer Institute
Caption: The CellMiner software suite, developed by the National Cancer Institute, provides the research community with greatly improved capacity to compare data derived from large collections of genomic information against thousands of drugs. By comparing drugs and genetic targets, researchers can more easily identify pharmaceuticals that could be effective against different forms of cancer. The newly updated software, called CellMiner, was built for use with the NCI-60, one of the most widely utilized collections of cancer cell samples employed in the testing of potential anti-cancer drugs.
Credit: National Cancer Institute
Usage Restrictions: None
Related news release: NIH tools facilitate matching cancer drugs with gene targets